MULTIPLE SCLEROSIS: NEW PATHOPHYSIOLOGICAL AND THERAPEUTIC CONCEPTS

1 Compston A G Ebers McDonald I McAlpine’s Multiple Sclerosis. Third edition. London: Churchill Livingstone; 1998.

2Multiple Sclerosis. Clinical Challenges and Controversies. In: Thompson AJ, Polman C, Hohlfeld R, editors. First edition. London: Martin Dunitz; 1997.

3 Miller DH J Kesselring McDonald WI Magnetic Resonance in Mutiple Sclerosis. First edition. Cambridge: Cambridge University Press; 1997.

4Principles of Treatments in Multiple Sclerosis. In: Hawkins CP, Wolinsky JS, editors. First edition. Oxford: Butterworth- Heinemann; 2000.

5 Whetten-Goldstein K FA Sloan Goldstein LB A comprehensive assessment of the cost of multiple sclerosis in the United States. Multiple Sclerosis 1998; 4:419-25.

6 Weinshenker BG B Bass Rice GP The natural history of multiple sclerosis: a geographically based study. I: clinical course and disability. Brain 1989; 112:133-46.

7 Poser CM DW Paty Scheinberg L New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neur 1983; 13:227-31.

8 O’Riordan JI AJ Thompson Kingsley DP The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121:495-503.

9 Ormerod IE DH Miller McDonald WI The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 1987; 110:1579-616.

10 Sailer M JI O’Riordan Thompson AJ Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52:599-606.

11 Martin R HF McFarland McFarlin DE. Immunological aspects of demyelinating diseases. Annual Review of Immunology 1992; 10:153-87.

12 Hvas J JR Oksenberg Fernando R Gamma delta T cell receptor repertoire in brain lesions of patients with multiple sclerosis. J Neuroimmunol 1993; 46:225-34.

13 Traugott U EL Reinherz Raine CS. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 1983; 4:201-21.

14 Esiri MM. Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol Appl Neurobiol 1980; 6:9-21.

15 Gran B B Hemmer Vergelli M Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 1999; 45:559-67.

16 Mann CL MB Davies Boggild MD Glutathione Stransferase polymorphisms in MS: their relationship to disability. Neurology 2000; 54:552-7.

17 Smith KJ R Kapoor Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.

18 Al-Omaishi J R Bashir Gendelman HE. The cellular immunology of multiple sclerosis. J Leukoc Biol 1999; 65: 444-52.

19 Ransohoff RM. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J Neuroimmunol 1999; 98:57-68.

20Bever CT Jr, Rosenberg GA. Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? Neurology 1999; 53:1380-1.

21 Lee MA J Palace Stabler G Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 122:191-7.

22 Ozenci V L Rinaldi Teleshova N Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimm 1999; 12:297-303.

23 Abbas AK KM Murphy Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93.

24 Mosmann TR Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-46.

25 Liblau RS SM Singer Th1 McDevitt HO. CD4+ Th2 T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-8.

26 Schmidt S. Candidate autoantigens in multiple sclerosis. Multiple Sclerosis 1999; 5:147-60.

27 Wekerle H K Kojima Lannes-Vieira J Animal models. Ann Neurol 1994; 36(Suppl):S47-S53.

28 Stinissen P Raus J. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting. Acta Neurol Belg 1999; 99:65-9.

29 Wolinsky JS. Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology 1995; 45:1245-7.

30 Johnson KP BR Brooks Cohen JA Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50:701-8.

31 Correale J W Gilmore McMillan M Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995; 154:2959-68.

32 Warren KG I Catz Johnson E Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994; 35:280-9.

33 Link H S Baig Jiang YP B-cells and antibodies in MS. Res Immunol 1989; 140:219-26.

34 Baig S T Olsson Yu-Ping J Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol 1991; 33:73-9.

35 Montag D KP Giese Bartsch V Mice deficient for the myelin associated associated glycoprotein show subtle abnormalities in myelin. Neuron 1994; 13:229-46.

36 Bernard CC TG Johns Slavin A Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997; 75:77-88.

37 Ben-Nun A I Mendel Bakimer R The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol 1996; 243: S14-22.

38 Kaye JF N Kerlero de Rosbo Mendel I The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). J Neuroimmunol 2000; 102:189-98.

39 Holz A B Bielekova Martin R Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol 2000; 164:1103-9

40 Warren KG Catz I. A myelin basic protein antibody cascade in purified IgG from cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1990; 96:19-27.

41 Warren KG Catz I. Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases. J Neurol Sci 1989; 91: 143-51.

42 Blancher A P Matsiota Guilbert B Autoantibodies in serum and CSF of patients with multiple sclerosis. Ann N Y Acad Sci 1988; 540:290-2.

43 Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979; 203:1123-5.

44 Prineas JW Macrophages Wright RG. , lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38:409-21.

45 Gerritse K C Deen Fasbender M The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J Neuroimmunol 1994; 49:153-9.

46 Raine CS B Cannella Hauser SL Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999; 46:144-60.

47 Genain CP B Cannella Hauser SL Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170-5.

48 Weinshenker BG PC O’Brien Petterson TM A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-86.

49 Lucchinetti C W Bruck Parisi J Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-17.

50 Katz D JK Taubenberger Cannella B Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-9.

51 Hawkins CP PM Munro MacKenzie F Duration and involvement of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113:365-78.

52 Miller DH P Rudge Johnson G Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111:927-39.

53 Losseff NA DP Kingsley McDonald WI Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996; 1:218-22.

54 Davie CA CP Hawkins Barker GJ Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117:49-58.

55 Youl BD G Turano Miller DH The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114:2437-50.

56 Lightman S WI McDonald Bird AC Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110:405-14.

57 Narayana PA TJ Doyle Lai D Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43:56-71.

58 Compston DA BP Morgan Campbell AK Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15:307-16.

59 Lassmann H. Neuropathology in multiple sclerosis: new concepts. Multiple Sclerosis 1998; 4:93-8.

60 Sriram S Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology 1997; 48:464-70.

61 Prineas JW EE Kwon Cho ES Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann N Y Acad Sci 1984; 436:11-32.

62 Scolding NJ PJ Rayner Compston DA. Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience 1999; 89:1-4.

63 Scolding N. Therapeutic strategies in multiple sclerosis. II. Long-term repair. Philos Trans R Soc Lond B Biol Sci 1999; 354:1711-20.

64 Blakemore WF Keirstead HS. The origin of remyelinating cells in the central nervous system. J Neuroimmunol 1999; 98:69-76.

65 Smith KJ McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999; 354:1649-73.

66 Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141:554-8.

67 Barnes D PM Munro Youl BD The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991; 114:1271-80.

68 Ferguson B MK Matyszak Esiri MM Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393-9.

69 Trapp BD J Peterson Ransohoff RM Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.

70 Lovas G N Szilagyi Majtenyi K Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123:308-17.

71 Bitsch A J Schuchardt Bunkowski S Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation. Brain 2000; 123:1174-83.

72 Arnold DL JS Wolinsky Matthews PM The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64(Suppl 1): S94-101.

73 Matthews PM E Pioro Narayanan S Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119:715-22.

74 Liu C S Edwards Gong Q Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 66:323-30.

75 Matthews PM N De Stefano Narayanan S Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18:327-36.

76De Stefano N, Matthews PM, Narayanan S Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997; 49:1138-41.

77 Narayanan S L Fu Pioro E Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41:385-91.

78 Filippi M C Tortorella Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Multiple Sclerosis 1999; 5: 273-82.

79 Lee MA AM Blamire Pendlebury S Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 2000; 57:65-70.

80 Fu L PM Matthews De Stefano N Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121:103-13.

81 Gonen O I Catalaa Babb JS Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54:15-9.

82 Davie CA NC Silver Barker GJ Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 1999; 67:710-5.

83 Losseff NA SL Webb JI O’Riordan , Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119:701-8.

84 Stevenson VL SM Leary Losseff NA Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998; 51:234-8.

85 Losseff NA L Wang Lai HM Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119:2009-19.

86 Davie CA GJ Barker Webb S Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118:1583-92.

87 Simon JH LD Jacobs Campion MK A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999; 53:139-48.

88 Coles AJ MG Wing Molyneux P Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296-304.

89 Jacobs L R Rudick Simon J. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics. J Neuroimmunol 2000; 107:167-73.

90The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRS Analysis Group. Interferonbeta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.

91 Paty DW Li DK. Interferon-beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43:662-7.

92 Weiller C SC Ramsay Wise RJ Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. Ann Neurol 1993; 33:181-9.

93 Werring DJ ET Bullmore Toosy AT Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 2000; 68:441-9.

94 Rose AS JW Kuzma Kurtzke JF Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo – final report. Neurology 1970; 20:1-59.

95 Miller H DJ Newell Ridley A. Multiple Sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; ii:1120-2.

96 Milligan NM R Newcombe Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50:511-6.

97 Minden SL J Orav Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 1988; 38:1631-4.

98 Kapoor R DH Miller Jones SJ Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50:230-7.

99 Thompson AJ C Kennard Swash M Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39:969-71.

100 Barnes MP DE Bateman Cleland PG Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48:157-9.

101 Frequin ST F Barkhof Lamers KJ The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. J Neuroimmunol 1992; 40:265-72.

102 Miller DH AJ Thompson Morrissey SP High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55:450-3.

103 Barkhof F MW Tas Frequin ST Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994; 36:382-7.

104 Burnham JA RR Wright Dreisbach J The effect of highdose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41:1349-54.

105 Beck RW PA Cleary Anderson MM Jr. A randomised, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326:581-8.

106 Beck RW PA Cleary Trobe JD The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329:1764-9.

107 Beck RW. The optic neuritis treatment trial: three-year followup results. Arch Ophthalmol 1995; 113:136-7.

108 Barnes D RA Hughes Morris RW Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902-6.

109 Reinhardt C JM Reul Melms A. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. Lancet 1997; 349:1697-8.

110 Yong VW S Chabot Stuve O Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682-9.

111The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRS Analysis Group. Interferon-beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85.

112The IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.

113 Jacobs LD DL Cookfair Rudick RA Intramuscular interferon-beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285-94.

114 Jacobs LD DL Cookfair Rudick RA A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Multiple Sclerosis 1995; 1:118-35.

115 Rudick RA DE Goodkin Jacobs LD Impact of interferonbeta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997; 49:358-63.

116 Simon JH LD Jacobs Campion M Magnetic resonance studies of intramuscular interferon-beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43:79-87.

117PRISMS (Prevention of Relapses and Disability by Interferonbeta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon-beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-504.

118The once weekly interferon for MS Study Group. Evidence of interferon-beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53:679-86.

119European Study Group on IFNB1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon-beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon-beta-1b in secondary progressive MS. Lancet 1998; 352:1491-7.

120 Knobler RL JI Greenstein Johnson KP Systemic recombinant human interferon-beta treatment of relapsingremitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993; 13:333-40.

121 Blumhardt LD. Interferon-beta-1a in relapsing-remitting multiple sclerosis: a meta analysis. Neurology 1999 (Abstract); 52:498.

122 Blumhardt LD DW Paty Hughes RAC Dosage effect of interferon-â-1a (Rebif) in preventing relapses and progression of disability in relapsing-remitting multiple sclerosis with baseline EDSS >3.5. J Neurol 1998; 245:371.

123 Weinshenker BG B Bass Rice GP The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989; 112:1419-28.

124 Filippi M MA Horsfield Morrissey SP Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-41.

125 Thompson AJ AG Kermode Wicks D Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29:53-62.

126 Runmarker B Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of followup. Brain 1993; 116:117-34.

127 Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunology Letters 1996; 50:1-15.

128 Arnon R M Sela Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol 1996;243:S8-13.

129 Bornstein MB A Miller Slagle S A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl J Med 1987; 317:408-14.

130 Johnson KP BR Brooks Cohen JA Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, doubleblind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-76.

131 Johnson KP BR Brooks Cohen JA Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50:701-8.

132 Comi G Filippi M for the glatiramer acetate MRI study group. The effect of glatiramer acetate on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo controlled study extended by open-label treatment. Neurology 1999 (Abstract); 52:289.

133 Bornstein MB A Miller Slagle S A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41:533-9.

134 Yudkin PL GW Ellison Ghezz A Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051-5.

135British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988; 2:179-83.

136 Confavreux C P Saddier Grimaud J Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46:1607-12.

137 Amato MP G Pracucci Ponziani G Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993; 43:831-3.

138 Palace J Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350:261.

139 Currier RD AF Haerer Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993; 56:1217-8.

140 Goodkin DE RA Rudick VanderBrug Medendorp S Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.

141 Goodkin DE RA Rudick VanderBrug Medendorp S Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47:1153-7.

142 Achiron A E Pras Gilad R Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49:1233-6.

143 Schuller E P Lambin Deloche G. Long-term treatment of multiple sclerosis with IgG immunotherapy. Pathologie Biologie 1996; 44:710-5.

144 Schuller E Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22:205-12.

145 Rothfelder U I Neu Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW – Munchener Medizinische Wochenschrift 1982; 124:74-8.

146 Rodriguez M Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27:12-7.

147 Van Engelen BG OR Hommes Pinckers A Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32:835-6.

148 Fazekas F F Deisenhammer Strasser-Fuchs S Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349:589-93.

149 Fazekas F F Deisenhammer Strasser-Fuchs S Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Multiple Sclerosis 1997; 3:137-41.

150 Achiron A U Gabbay Gilad R Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398-402.

151 Sorensen PS B Wanscher Jensen CV Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-81.

152 Cook SD R Troiano Rohowsky-Kochan C Intravenous gamma globulin in progressive MS. Acta Neurol Scand 1992;86:171-5.

153 Mauch E HH Kornhuber Krapf H Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992; 242:96-102.

154 Krapf H E Mauch Fetzer U Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995; 37:113-9.

155 Noseworthy JH MB Hopkins Vandervoort MK An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43:1401-6.

156 Millefiorini E C Gasperini Pozzilli C Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244:153-9.

157 Edan G D Miller Clanet M Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62:112-8.

158 Hartung HP RE Gonsette the MIMS study group. Mitoxanthrone in progressive multiple sclerosis: a placebo controlled, randomised, observer-blind European phase III multicentre study. Clinical data. Multiple Sclerosis 1998 (Abstract); 4:325.

159 Krapf H S Morrissey Zenker O Mitoxanthrone in progressive multiple sclerosis: a placebo-controlled, randomised, observer blind European phase III multicentre study. MRI data. Multiple Sclerosis 1998 (Abstract); 4:380.

160De Forni M, Armand JP. Cardiotoxicity of chemotherapy. Curr Opin Oncol 1994; 6:340-4.

161 Khatri BO MP McQuillen Harrington GJ Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35:312-9.

162 Khatri BO MP McQuillen Hoffmann RG Plasma exchange in chronic progressive multiple sclerosis: a longterm study. Neurology 1991; 41:409-14.

163The Canadian cooperative MS study group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991; 337:441-6.

164 Weiner HL PC Dau Khatri BO Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143-9.

165 Rodriguez M WE Karnes Bartleson JD Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43:1100-4.

166The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol 1990; 27:591-605.

167 Zhao GJ DK Li Wolinsky JS Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group. J Neuroimaging 1997; 7:1-7.

168 Kappos L U Patzold Dommasch D Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis – results of the German multicenter study. Ann Neurol 1988; 23:56-63.

169 Rudge P JC Koetsier Mertin J Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol, Neurosurg Psychiat 1989; 52:559-65.

170 Hauser SL DM Dawson Lehrich JR Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-80.

171 Carter JL DA Hafler Dawson DM Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988; 38:9-14.

172 Cook SD C Devereux Troiano R Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Scand 1995; 91:22-7.

173 Cook SD C Devereux Troiano R Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol 1987; 22:634-8.

174Anonymous. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457-65.

175 Noseworthy JH P O’Brien Erickson BJ The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998; 51:1342-52.

176 Andersen O J Lycke Tollesson PO Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47:895-900.

177 Karussis DM Z Meiner Lehmann D Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebocontrolled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47:341-6.